Epizyme Inc
F:EPE
Epizyme Inc
EPS (Diluted)
Epizyme Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Epizyme Inc
F:EPE
|
EPS (Diluted)
-$1
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-26%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$7
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
-$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$38
|
CAGR 3-Years
-19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
Epizyme Inc
Glance View
Nestled in the bustling world of biotechnology, Epizyme Inc. emerged as a dynamic player within the realm of epigenetic medicine. The company carved a niche for itself by focusing on the development and commercialization of novel therapeutics that target the epigenetic regulation of gene expression. Founded with a vision to harness the power of small molecules to modulate the proteins responsible for reading and interpreting the epigenetic code, Epizyme strives to innovate therapies that can treat patients with serious unmet medical conditions, particularly in oncology. Its flagship product, Tazemetostat, received FDA approval for the treatment of certain types of lymphoma and soft tissue sarcoma. This marked a significant milestone for the company, confirming its ability to transform complex biological science into tangible, market-ready solutions. With a strategic approach centered on precision medicine, Epizyme monetizes its innovations primarily through direct sales, partnerships, and licensing agreements. The company’s revenue streams are buoyed by its collaborations with other biotechnology and pharmaceutical companies keen on leveraging Epizyme’s specialized expertise to advance their own drug development programs. Moreover, by advancing a robust pipeline of epigenetic therapies that span a variety of therapeutic areas, Epizyme positions itself to capture a growing share of the biotechnology market. Intellectual property and sophisticated R&D capabilities underpin its business model, enabling the company not only to produce groundbreaking therapies but also to secure significant market opportunities in an increasingly competitive landscape.
See Also
What is Epizyme Inc's EPS (Diluted)?
EPS (Diluted)
-1.2
USD
Based on the financial report for Jun 30, 2022, Epizyme Inc's EPS (Diluted) amounts to -1.2 USD.
What is Epizyme Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
10%
Over the last year, the EPS (Diluted) growth was 51%. The average annual EPS (Diluted) growth rates for Epizyme Inc have been 7% over the past three years , 10% over the past five years .
You don't have any saved screeners yet